MYGN
Price
$4.01
Change
-$0.06 (-1.47%)
Updated
May 22, 12:46 PM (EDT)
Capitalization
1.93B
70 days until earnings call
WAT
Price
$348.36
Change
+$1.00 (+0.29%)
Updated
May 22, 04:56 PM (EDT)
Capitalization
20.38B
75 days until earnings call
Interact to see
Advertisement

MYGN vs WAT

Header iconMYGN vs WAT Comparison
Open Charts MYGN vs WATBanner chart's image
Myriad Genetics
Price$4.01
Change-$0.06 (-1.47%)
Volume$870
Capitalization1.93B
Waters
Price$348.36
Change+$1.00 (+0.29%)
Volume$700
Capitalization20.38B
MYGN vs WAT Comparison Chart
Loading...
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MYGN vs. WAT commentary
May 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MYGN is a Hold and WAT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 22, 2025
Stock price -- (MYGN: $4.07 vs. WAT: $347.36)
Brand notoriety: MYGN and WAT are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: MYGN: 102% vs. WAT: 133%
Market capitalization -- MYGN: $1.93B vs. WAT: $20.38B
MYGN [@Medical Specialties] is valued at $1.93B. WAT’s [@Medical Specialties] market capitalization is $20.38B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.5B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MYGN’s FA Score shows that 1 FA rating(s) are green whileWAT’s FA Score has 0 green FA rating(s).

  • MYGN’s FA Score: 1 green, 4 red.
  • WAT’s FA Score: 0 green, 5 red.
According to our system of comparison, WAT is a better buy in the long-term than MYGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MYGN’s TA Score shows that 4 TA indicator(s) are bullish while WAT’s TA Score has 5 bullish TA indicator(s).

  • MYGN’s TA Score: 4 bullish, 4 bearish.
  • WAT’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, both MYGN and WAT are a good buy in the short-term.

Price Growth

MYGN (@Medical Specialties) experienced а +5.99% price change this week, while WAT (@Medical Specialties) price change was +0.57% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.59%. For the same industry, the average monthly price growth was +7.19%, and the average quarterly price growth was -0.08%.

Reported Earning Dates

MYGN is expected to report earnings on Jul 31, 2025.

WAT is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Medical Specialties (+0.59% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
WAT($20.4B) has a higher market cap than MYGN($1.93B). WAT YTD gains are higher at: -6.367 vs. MYGN (-70.314). WAT has higher annual earnings (EBITDA): 1B vs. MYGN (-197.4M). WAT has more cash in the bank: 396M vs. MYGN (141M). MYGN has less debt than WAT: MYGN (152M) vs WAT (2.44B). WAT has higher revenues than MYGN: WAT (2.96B) vs MYGN (753M).
MYGNWATMYGN / WAT
Capitalization1.93B20.4B9%
EBITDA-197.4M1B-20%
Gain YTD-70.314-6.3671,104%
P/E RatioN/A31.78-
Revenue753M2.96B25%
Total Cash141M396M36%
Total Debt152M2.44B6%
FUNDAMENTALS RATINGS
MYGN vs WAT: Fundamental Ratings
MYGN
WAT
OUTLOOK RATING
1..100
411
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
10047
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
9750
P/E GROWTH RATING
1..100
260
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

WAT's Valuation (80) in the Medical Specialties industry is in the same range as MYGN (97) in the Biotechnology industry. This means that WAT’s stock grew similarly to MYGN’s over the last 12 months.

WAT's Profit vs Risk Rating (47) in the Medical Specialties industry is somewhat better than the same rating for MYGN (100) in the Biotechnology industry. This means that WAT’s stock grew somewhat faster than MYGN’s over the last 12 months.

WAT's SMR Rating (100) in the Medical Specialties industry is in the same range as MYGN (100) in the Biotechnology industry. This means that WAT’s stock grew similarly to MYGN’s over the last 12 months.

WAT's Price Growth Rating (50) in the Medical Specialties industry is somewhat better than the same rating for MYGN (97) in the Biotechnology industry. This means that WAT’s stock grew somewhat faster than MYGN’s over the last 12 months.

MYGN's P/E Growth Rating (2) in the Biotechnology industry is somewhat better than the same rating for WAT (60) in the Medical Specialties industry. This means that MYGN’s stock grew somewhat faster than WAT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MYGNWAT
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
66%
Bearish Trend 2 days ago
63%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
58%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
66%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
67%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
64%
Advances
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 7 days ago
67%
Declines
ODDS (%)
Bearish Trend 9 days ago
81%
Bearish Trend 9 days ago
61%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
65%
Bearish Trend 2 days ago
53%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
67%
View a ticker or compare two or three
Interact to see
Advertisement
MYGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
WAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGOTX15.45N/A
N/A
Goldman Sachs Mid Cap Growth Inv
MFLLX15.82N/A
N/A
Morgan Stanley Inst Inception R6
QUAZX69.80N/A
N/A
AB Small Cap Growth Z
TRHZX156.44N/A
N/A
T. Rowe Price Equity Index 500 Z
RLUSX16.25-0.30
-1.81%
Lazard US Equity Focus R6

MYGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, MYGN has been loosely correlated with WAT. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if MYGN jumps, then WAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MYGN
1D Price
Change %
MYGN100%
-8.54%
WAT - MYGN
39%
Loosely correlated
-4.07%
ATEC - MYGN
34%
Loosely correlated
-2.39%
ICUI - MYGN
31%
Poorly correlated
-3.09%
VCYT - MYGN
31%
Poorly correlated
-4.17%
AORT - MYGN
31%
Poorly correlated
-2.13%
More